论文部分内容阅读
目的:观察自体DC联合CIK细胞治疗晚期乳腺癌患者的安全性及临床疗效,并分析相关预后因素。方法:回顾性分析2011年8月至2014年12月在解放军第81医院进行DC-CIK细胞治疗的42例晚期乳腺癌患者临床资料,采用实体瘤疗效评价标准评价近期疗效,并观察DC-CIK细胞治疗的安全性。分析患者生存期,评价远期疗效,单因素及多因素分析预后因素,并采用配对t检验分析患者治疗前后免疫功能。结果:42例晚期乳腺癌患者经DC-CIK细胞治疗后,客观缓解率为38.1%(16/42),疾病控制率为61.9%(26/42);1年生存率为59%,2年生存率为48%,3年生存率为48%;肿瘤标记物CA153治疗后显著性降低;外周血淋巴细胞亚群除辅助性T细胞(CD3~+CD4~+)水平显著性升高外,其他淋巴细胞亚群无显著性变化。单因素分析结果显示,肿瘤部位(P=0.012)、治疗前CA153水平(P=0.000)是DC-CIK细胞治疗预后的影响因素;多因素分析结果显示,治疗前CA153水平(P=0.003)是DC-CIK细胞治疗的独立预后因素。结论:晚期乳腺癌患者经DC-CIK细胞治疗后,无明显不良反应,可能提高患者长期生存率,产生临床获益,安全可行。
Objective: To observe the safety and clinical efficacy of autologous DC combined with CIK cells in the treatment of patients with advanced breast cancer and to analyze the related prognostic factors. Methods: The clinical data of 42 patients with advanced breast cancer who underwent DC-CIK cell therapy from the 81st Hospital of Chinese People’s Liberation Army from August 2011 to December 2014 were retrospectively analyzed. The curative effect of solid tumor was evaluated to evaluate the short-term curative effect. DC-CIK Cell therapy safety. Analysis of patient survival, evaluation of long-term efficacy, univariate and multivariate analysis of prognostic factors, and paired t-test analysis of patients with immune function before and after treatment. Results: The objective response rate was 38.1% (16/42) in 42 patients with advanced breast cancer after treatment with DC-CIK cells. The disease control rate was 61.9% (26/42). The 1-year survival rate was 59% The survival rate was 48% and the 3-year survival rate was 48%. The tumor marker CA153 was significantly decreased after treatment. The levels of CD3 + CD4 + in peripheral blood lymphocyte subsets were significantly increased, No significant changes in other lymphocyte subsets. The results of univariate analysis showed that the tumor location (P = 0.012) and the level of CA153 before treatment (P = 0.000) were the prognostic factors of DC-CIK cells. Multivariate analysis showed that the level of CA153 before treatment was significantly higher than that before treatment Independent prognostic factors for DC-CIK cell therapy. Conclusion: The patients with advanced breast cancer treated with DC-CIK cells have no obvious adverse reactions, which may improve the long-term survival rate of patients with breast cancer and produce clinical benefits, which is safe and feasible.